FRANKFORT, Mich., May 11 /PRNewswire/ -- The following is being released today by Howard E. Greene, Jr. To my fellow shareholders: As the founding CEO of Amylin and a board member for almost 22 years, I want you to know how I plan to vote at our annual meeting. In my opinion Amylin's talented employee team has created one of the best product and technology platforms in the diabetes and obesity area. But, shareholders have suffered because sales results have not reflected the commercial potential of that platform. I commend our present management team, under Dan Bradbury's leadership, for recognizing that they need to achieve a more effective working relationship with Lilly, and that they must design a more innovative strategy for convincing primary care physicians that Amylin's injectible medicines are their best treatment option for patients with diabetes. Our board of directors will play a strategic role in meeting these challenges. I believe management will have more freedom to think outside of the box if we replace the directors most directly involved in crafting the disappointing commercialization strategy. Also, with the departures of Ginger Graham and me, the Amylin board loses more than 60% of its stock ownership. I think our investors would be well served by adding directors who directly represent large shareholdings. So, I have decided to vote for the slate proposed by Eastbourne, including the Icahn nominees. Respectfully, Howard E. Greene, Jr., Co-Founder of Amylin DATASOURCE: Howard E. Greene, Jr. CONTACT: Howard E. Greene, Jr., , +1-212-858-1685 (email contact is preferable)

Copyright